The aspect of Pfizer's coronavirus vaccine that really stunned the company's scientists was the fact that vaccinated participants in the Phase 3 efficacy trial had protections against the pathogen by day 12, a time at which there was barely any antibody response, Stat News reports. "That was the biggest surprise," said Vidia Roopchand, Pfizer's principal scientist for viral vaccines.
Roopchand is still trying to figure exactly why that is — not that it's a bad thing — by poring over the data. One possibility is that other aspects of the immune system such as T-cells that Roopchand says have largely been neglected in immunology research may have played a significant role. It's possible, he suggested, that's more important to measure cellular immunity than look for a robust antibody response. "The 12-day protection data is telling us there's more to it," Roopchand told Stat. "This is a great time to learn."
He also indicated that the discovery could affect future vaccine development, regardless of the virus. Before, vaccine candidates would likely get tossed to the side if they didn't produce a strong antibody response in animal testing, but a deeper look at the rest of the immune system could change that approach. Read more at Stat News.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Remaking the military: the war on diversity and ‘fat generals’Talking Point The US Secretary of War addressed military members on ‘warrior ethos’
-
The delightful, smutty world of Jilly CooperIn the Spotlight Millions mourn the ‘Mrs Kipling of sex’
-
Codeword: October 11, 2025The Week's daily codeword puzzle
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defectsThe Explainer The virus can show no symptoms in adults
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
